Related Experiment Video
Updated: Mar 13, 2026
Transcorporal Artificial Urinary Sphincter Cuff Placement in a Case Requiring Revision for Urethral Atrophy
Published on: June 16, 2022
The impact of androgen deprivation on artificial urinary sphincter outcomes
George C Bailey1, Brian J Linder1, Marcelino E Rivera1
1Department of Urology, Mayo Clinic, Rochester, Minnesota, USA.
Background:
Androgen deprivation therapy (ADT) causes systemic tissue atrophy. It is unclear if this tissue atrophy adversely impacts artificial urinary sphincter (AUS) outcomes. We sought to evaluate the effect of ADT on adverse AUS outcomes.
Methods:
We retrospectively identified 518 men undergoing primary AUS placement at our institution between 1998 and 2014. Rates of device explant for infection/erosion, mechanical failure, and urethral atrophy in men with >6 months of ADT use within 2 years prior to AUS placement were compared to ADT naive men.
Results:
Fifty of the patients (50/518, 9.7%) had >6 months of ADT use within 2 years prior to AUS placement while 442 were ADT naive. Multivariable survival analysis of AUS events by competing risks failed to show any effect of ADT on device explantation for infection/erosion (HR 1.12, P=0.68), replacement for mechanical failure (HR 0.92, P=0.77), or urethral atrophy (HR 0.77, P=0.46).
Conclusions:
This study did not show evidence supporting differences in adverse AUS outcomes between men with ADT use and ADT naive men.
